Impact of ABCG2 polymorphisms on the clinical outcome of TKIs therapy in Chinese advanced non-small-cell lung cancer patients

• DOI: 10.1186/s12935-015-0191-3
• Publication Date: 2015-04-18T00:33:37Z
• Authors: Xueqin Chen; Dadong Chen; Shaoyu Yang; Ruobing Ma; Yuelong Pan; Xin Li; Shenglin Ma
• Keywords: Abcg2

The primary purpose of this study was to investigate the correlation between single nucleotide polymorphisms (SNPs) ATP binding cassette superfamily G member 2 (ABCG2) and outcome tyrosine kinase inhibitions (TKIs) therapy in Chinese advanced non-small-cell lung cancer (NSCLC) patients. secondary objective identify biomarkers evaluate response treatment targeted therapy.SNP genotyping (34 G/A, 421 C/A, 1143 C/T -15622 C/T) ABCG2 gene 100 patients performed using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. clinical characteristics were collected. A total 70 treated with TKIs (gefitinib, erlotinib icotinib). association evaluated. Kaplan-Meier survival curves plotted for overall (OS) analyzed log-rank test.The three 34 C/A occurred more frequently compared NSCLC There no (p > 0.05). median OS GG genotype at position significantly shorter than those GA or AA < No significant difference found 0.05).ABCG2 G/A may be a possible predictor